Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Helper Innate Lymphoid Cells as Cell Therapy for Cancer

Version 1 : Received: 5 September 2022 / Approved: 6 September 2022 / Online: 6 September 2022 (03:17:36 CEST)

A peer-reviewed article of this Preprint also exists.

Magnusson, F. C.; Bahhar, I. Helper Innate Lymphoid Cells as Cell Therapy for Cancer. Immunology, 2022, 168, 569–579. https://doi.org/10.1111/imm.13599. Magnusson, F. C.; Bahhar, I. Helper Innate Lymphoid Cells as Cell Therapy for Cancer. Immunology, 2022, 168, 569–579. https://doi.org/10.1111/imm.13599.

Abstract

Although the first cancer immunotherapy was given in the clinic more than a century ago, this line of treatment has remained more of a distant goal than a practical therapy due to limited understanding of the tumor microenvironment and the mechanisms at play within it, which lead to failures of numerous clinical trials. However, in the last two decades, the immune checkpoint inhibitors and chimeric antigen receptor-T cell therapies have revolutionized the treatment of cancer and provided proof-of-concept that immunotherapies are a viable option. So far, immunotherapies have majoritarily focused on utilizing T cells, however T cells are not autonomous but rather function as part of, and therefore are influenced by, a vast cast of other immune cells, including innate lymphoid cells (ILCs). Here, we summarize the role of ILCs, especially helper ILCs, in tumor development, progression and metastasis, as well as their potential to be used as immunotherapy for cancer. By reviewing the studies that used helper ILCs as adoptive cell therapy, we highlight the rationale behind considering these cells as novel adoptive cell therapy for cancer as well as identify open questions and areas for future research.

Keywords

innate lymphoid cells; cell therapy; cancer; immunotherapy; antitumor immune response; adoptive cell therapy

Subject

Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.